Skip to content

Kidney and Pregnancy Registry

Kidney and Pregnancy Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06067867
Enrollment
600
Registered
2023-10-05
Start date
2023-09-12
Completion date
2043-12-31
Last updated
2023-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Brief summary

Maternal physiological adaptation to pregnancy plays an important role in the smooth progress of the pregnancy and the healthy growth of the fetus. This physiological adaptation takes place at the level of several organs, including the kidney. Physiological changes during a normal pregnancy take place at the anatomical, glomerular and tubular level. In the event of pre-existing kidney damage (glomerular and tubular diseases, stone disease, high blood pressure (hypertension) etc...) these adaptations will not be optimal. This will have implications for: * the course of the pregnancy with the occurrence of feto-maternal complications: miscarriages, pre-eclampsia, intrauterine growth retardation (IUGR), low birth weight, prematurity. The risk of feto-maternal complications increases with the degree of renal failure or with certain pathologies such as lupus. * progression of kidney disease Some maternal complications have long-term implications: preeclampsia is associated with a high risk of subsequent cardiovascular and renal complications. Pregnancies in these patients are high-risk pregnancies and require specialized management by an experienced group of gynecologists and nephrologists. The creation of a retrospective and prospective register by collecting demographic, clinical, biological, radiological and genetic data concerning patients at each consultation within the CHU Brugmann Hospital will allow: * to establish the epidemiological and clinico-biological characteristics of the patients followed at the Kidney and Pregnancy Clinic at the CHU Brugmann Hospital * to analyze the risk factors for feto-maternal complications * to analyze the risk factors for the occurrence of subsequent cardio-renal pathologies in patients who have had preeclampsia or an event during their pregnancy * to identify patients who will need specialized genetic testing

Interventions

Data extraction from medical files

Sponsors

Brugmann University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

1. Pre-conception consultations Woman of childbearing age with: * Renal damage (glomerular, tubular disease, renal lithiasis, systemic disease, metabolic diseases, congenital diseases, etc.) * Hematological disorders (sickle cell disease) * Kidney transplantation * High blood pressure (hypertension) * Pre-kidney transplant assessment in progress for discussion of contraception and pregnancy after kidney transplantation * Preeclampsia * Multiple miscarriages * IUGR and low birth weight in the fetus * Family history of kidney disease 2. Peri-gravid consultations Pregnant women with * Pre-existing kidney damage * De novo renal failure (IR) * Proteinuria * Hematuria * Chronic hypertension * Pregnancy hypertension * Renal lithiasis 3. Postpartum consultations Postpartum women with * Early/late pre-eclampsia * Eclampsia / Hemolysis Elevated Liver enzymes Low Platelet (HELLP) syndrome * Pregnancy hypertension * Postpartum hemorrhage * De novo renal failure postpartum

Exclusion criteria

Male patients Menopausal patients

Design outcomes

Primary

MeasureTime frameDescription
Epidemiological characteristics of patients20 years
Clinico-biological characteristics of patients20 years
Risk factors for feto-maternal complications20 years
Risk factors for cardio-renal pathologies20 yearsRisk factors for the occurrence of subsequent cardio-renal pathologies in patients who had preeclampsia or an event during their pregnancy
Need for genetic testing20 yearsIdentification of patients who will need specialized genetic testing

Countries

Belgium

Contacts

Primary ContactChristelle Fosso
Christelle.FOSSO@chu-brugmann.be3224772016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026